Loyal raises $45M Series B led by Bain Capital Ventures to seek approval for LOY-002 and finish the STAY study

Loyal/LOY-002

Loyal raised a $45M Series B led by Bain Capital Ventures with Valor Equity Partners joining, bringing total funding past $125M. The capital supports completion of the STAY pivotal study of LOY-002 and advancement of regulatory approval work for the senior-dog lifespan extension drug.

• $45M Series B led by Bain Capital Ventures, a new investor; round oversubscribed at 2x with significant markup to 2021 Series A.
• Valor Equity Partners joined; returning backers increased their commitments.
• Total funding >$125M; capital supports STAY study completion and LOY-002 regulatory pathway toward conditional approval.